毕得医药股价跌5.04%，易方达基金旗下1只基金位居十大流通股东，持有90万股浮亏损失315万元

Group 1 - Bid Medicine's stock price fell by 5.04% on January 20, closing at 66.00 yuan per share, with a trading volume of 52.74 million yuan and a turnover rate of 1.81%, resulting in a total market capitalization of 5.998 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.12% during this period [1] - Bid Medicine focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among the top ten circulating shareholders of Bid Medicine, a fund under E Fund, specifically E Fund Value Growth Mixed Fund (110010), entered the top ten with 900,000 shares, accounting for 2.08% of circulating shares [2] - The estimated floating loss for E Fund Value Growth Mixed Fund today is approximately 3.15 million yuan, with a total floating loss of 4.077 million yuan during the three-day decline [2] - E Fund Value Growth Mixed Fund has a total asset size of 3.288 billion yuan, with a year-to-date return of 3.74% and a one-year return of 38.06% [2]